Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: The effect on serum IL-1 and IL-6 levels and bone mineral density

Nephron

Volumn 90, Issue 2, 2002, Pages 188-194

  Türk, Süleyman ^a   Akbulut, Mehmet ^a   Yildiz, Alaattin ^b   Gürbilek, Mehmet ^a   Gönen, Said ^a   Tombul, Zeki ^a   Yeksan, Mehdi ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bone remodelling; Calcitriol; Cytokines; Intact; Interleukin 1 ; Interleukin 6; Osteodystrophy; Parathyroid hormone; Renal

Indexed keywords

CALCITRIOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; PARATHYROID HORMONE;

ADULT; AGE; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; BONE DENSITY; BONE REMODELING; CALCITRIOL; CALCIUM CHANNEL AGONISTS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-1; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PULSE THERAPY, DRUG; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 0036294008     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049041     Document Type: Article

References (38)

1. Renal osteodystrophy
2. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease
3. Evaluation of IGF system component levels and mitogenic activity of uremic serum on normal human osteoblasts
4. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy
5. Cellular mechanisms of renal osteodystrophy
6. Role of cytokines in renal osteodystrophy
7. The role of cytokines in skeletal remodelling: Possible consequences for renal osteodystrophy
8. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients
9. Intravenous versus oral calcitriol therapy in renal osteodystrophy: Result of a prospective, pulsed and dose-comparable study
10. The effect of oral 1α-hydroxyclaciferol treatment on bone mineral density in hemodialysis patients
11. Maintenance of bone mass in patients receiving dialytic therapy
12. Calcitriol and calcium carbonate therapy in early chronic renal failure
13. Comparison of intermittent oral and intravenous calcitriol in he-modialysis patients with secondary hyperparathyroidism
14. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study
15. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients
16. A role for interleukin 6 in parathroid hormone-induced bone resorption in vivo
17. Circulating levels of interleukin 6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption. A clinical research center study
18. Relationship between soluble markers of immmune activation and bone turnover in postmenopausal women with rheumatoid arthritis
19. Osteoclasts constitutively express regulators of bone resorption: An immunohistochemical and in situ hybridization study
20. Bone resorption and mRNA expression of IL6 and IL6 receptor in patients with renal osteodystrophy
21. Serum interleukin 6 in renal osteodystrophy: Relationship with serum PTH and bone remodelling markers
22. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α
23. Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3
24. 3 modulation of TNF and IL-1β gene expression in human peripheral blood mononuclear cells and monocytoid cell lines
25. 3
26. Effect of vitamin D3 on interleukin-6 synthesis induced by prostaglandins in osteoblasts
27. Vitamin D therapy modulates cytokine secretion in patients with renal failure
28. Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease
29. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure
30. 3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis
31. Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure
32. 3 in patients on chronic hemodialysis
33. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25 dihydroxycholecalciferol in uremic patients
34. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients
35. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
36. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy
37. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol
38. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism